{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:56:12Z","timestamp":1790949372841,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2015,4,22]],"date-time":"2015-04-22T00:00:00Z","timestamp":1429660800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s40263-015-0244-0","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T07:17:22Z","timestamp":1429600642000},"page":"383-395","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Topiramate in Alcohol Use Disorders: Review and Update"],"prefix":"10.1007","volume":"29","author":[{"given":"Riccardo","family":"Guglielmo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Quatrale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Ioime","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irket","family":"Kadilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Di Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Janiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,22]]},"reference":[{"issue":"2","key":"244_CR1","first-page":"144","volume":"21","author":"CF Valenzuela","year":"1997","unstructured":"Valenzuela CF. Alcohol and neurotransmitter interactions. Alcohol Health Res World. 1997;21(2):144\u20138.","journal-title":"Alcohol Health Res World."},{"issue":"1","key":"244_CR2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1530-0277.1997.tb03733.x","volume":"21","author":"TI Mueller","year":"1997","unstructured":"Mueller TI, Stout RL, Rudden S, Brown RA, Gordon A, Solomon DA, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol Clin Exp Res. 1997;21(1):86\u201392.","journal-title":"Alcohol Clin Exp Res."},{"issue":"2","key":"244_CR3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1300\/J069v21n02_05","volume":"21","author":"LP Longo","year":"2002","unstructured":"Longo LP, Campbell T, Hubatch S. Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention. J Addict Dis. 2002;21(2):55\u201364.","journal-title":"J Addict Dis."},{"issue":"9370","key":"244_CR4","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","volume":"361","author":"BA Johnson","year":"2003","unstructured":"Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677\u201385.","journal-title":"Lancet."},{"issue":"3","key":"244_CR5","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/hup.833","volume":"22","author":"G Martinotti","year":"2007","unstructured":"Martinotti G, Di Nicola M, Romanelli R, Andreoli S, Pozzi G, Moroni N, et al. High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients. Hum Psychopharmacol. 2007;22(3):149\u201356.","journal-title":"Hum Psychopharmacol."},{"issue":"11","key":"244_CR6","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4088\/JCP.v68n1108","volume":"68","author":"FA Furieri","year":"2007","unstructured":"Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(11):1691\u2013700.","journal-title":"J Clin Psychiatry."},{"issue":"11","key":"244_CR7","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s12325-012-0061-5","volume":"29","author":"R Guglielmo","year":"2012","unstructured":"Guglielmo R, Martinotti G, Clerici M, Janiri L. Pregabalin for alcohol dependence: a critical review of the literature. Adv Ther. 2012;29(11):947\u201357.","journal-title":"Adv Ther."},{"issue":"19","key":"244_CR8","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2174\/138161210791516404","volume":"16","author":"BA Johnson","year":"2010","unstructured":"Johnson BA, Ait-Daoud N. Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients. Curr Pharm Des. 2010;16(19):2103\u201312.","journal-title":"Curr Pharm Des."},{"issue":"2","key":"244_CR9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2174\/1874473710902020135","volume":"2","author":"GA Kenna","year":"2009","unstructured":"Kenna GA, Lomastro TL, Schiesl A, Leggio L, Swift RM. Review of topiramate: an antiepileptic for the treatment of alcohol dependence. Curr Drug Abuse Rev. 2009;2(2):135\u201342.","journal-title":"Curr Drug Abuse Rev."},{"issue":"10","key":"244_CR10","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1345\/aph.1L157","volume":"42","author":"CL Olmsted","year":"2008","unstructured":"Olmsted CL, Kockler DR. Topiramate for alcohol dependence. Ann Pharmacother. 2008;42(10):1475\u201380.","journal-title":"Ann Pharmacother."},{"issue":"1","key":"244_CR11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/187152710790966696","volume":"9","author":"A Sousa De","year":"2010","unstructured":"De Sousa A. The role of topiramate and other anticonvulsants in the treatment of alcohol dependence: a clinical review. CNS Neurol Disord Drug Targets. 2010;9(1):45\u20139.","journal-title":"CNS Neurol Disord Drug Targets."},{"issue":"5","key":"244_CR12","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1586\/14737175.4.5.751","volume":"4","author":"BA Johnson","year":"2004","unstructured":"Johnson BA. Uses of topiramate in the treatment of alcohol dependence. Expert Rev Neurother. 2004;4(5):751\u20138.","journal-title":"Expert Rev Neurother."},{"issue":"Suppl 1","key":"244_CR13","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","volume":"41","author":"RP Shank","year":"2000","unstructured":"Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(Suppl 1):S3\u20139.","journal-title":"Epilepsia."},{"issue":"1\u20132","key":"244_CR14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0006-8993(98)00785-9","volume":"807","author":"H Kawasaki","year":"1998","unstructured":"Kawasaki H, Tancredi V, D\u2019Arcangelo G, Avoli M. Multiple actions of the novel anticonvulsant drug topiramate in the rat subiculum in vitro. Brain Res. 1998;807(1\u20132):125\u201334.","journal-title":"Brain Res."},{"issue":"Suppl 1","key":"244_CR15","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1111\/j.1528-1157.2000.tb02165.x","volume":"41","author":"HS White","year":"2000","unstructured":"White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia. 2000;41(Suppl 1):S17\u201320.","journal-title":"Epilepsia."},{"issue":"4","key":"244_CR16","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1471-4159.2005.03259.x","volume":"94","author":"M Angehagen","year":"2005","unstructured":"Angehagen M, Ronnback L, Hansson E, Ben-Menachem E. Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. J Neurochem. 2005;94(4):1124\u201330.","journal-title":"J Neurochem."},{"issue":"Suppl 1","key":"244_CR17","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1111\/j.1528-1157.2000.tb02173.x","volume":"41","author":"X Zhang","year":"2000","unstructured":"Zhang X, Velumian AA, Jones OT, Carlen PL. Modulation of high-voltage-activated calcium channels in dentate granule cells by topiramate. Epilepsia. 2000;41(Suppl 1):S52\u201360.","journal-title":"Epilepsia."},{"issue":"Suppl 1","key":"244_CR18","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1111\/j.1528-1157.2000.tb06047.x","volume":"41","author":"SJ Dodgson","year":"2000","unstructured":"Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia. 2000;41(Suppl 1):S35\u20139.","journal-title":"Epilepsia."},{"issue":"2","key":"244_CR19","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0028-3908(01)00171-X","volume":"42","author":"AI Herrero","year":"2002","unstructured":"Herrero AI, Del Olmo N, Gonzalez-Escalada JR, Solis JM. Two new actions of topiramate: inhibition of depolarizing GABA(A)-mediated responses and activation of a potassium conductance. Neuropharmacology. 2002;42(2):210\u201320.","journal-title":"Neuropharmacology."},{"issue":"2","key":"244_CR20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0920-1211(95)00105-0","volume":"24","author":"A Wauquier","year":"1996","unstructured":"Wauquier A, Zhou S. Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res. 1996;24(2):73\u20137.","journal-title":"Epilepsy Res."},{"issue":"2","key":"244_CR21","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.160.2.255","volume":"160","author":"SL McElroy","year":"2003","unstructured":"McElroy SL, Arnold LM, Shapira NA, Keck PE Jr, Rosenthal NR, Karim MR, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(2):255\u201361.","journal-title":"Am J Psychiatry."},{"issue":"11","key":"244_CR22","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1528-1157.1999.tb02029.x","volume":"40","author":"JM Rho","year":"1999","unstructured":"Rho JM, Sankar R. The pharmacologic basis of antiepileptic drug action. Epilepsia. 1999;40(11):1471\u201383.","journal-title":"Epilepsia."},{"issue":"3","key":"244_CR23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/syn.10000","volume":"42","author":"WK Schiffer","year":"2001","unstructured":"Schiffer WK, Gerasimov MR, Marsteller DA, Geiger J, Barnett C, Alexoff DL, et al. Topiramate selectively attenuates nicotine-induced increases in monoamine release. Synapse. 2001;42(3):196\u20138.","journal-title":"Synapse."},{"issue":"Suppl 1","key":"244_CR24","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1111\/j.1528-1157.2000.tb02174.x","volume":"41","author":"WR Garnett","year":"2000","unstructured":"Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia. 2000;41(Suppl 1):S61\u20135.","journal-title":"Epilepsia."},{"issue":"8","key":"244_CR25","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2174\/138920008786049311","volume":"9","author":"M Mula","year":"2008","unstructured":"Mula M. Anticonvulsants\u2013antidepressants pharmacokinetic drug interactions: the role of the CYP450 system in psychopharmacology. Curr Drug Metab. 2008;9(8):730\u20137.","journal-title":"Curr Drug Metab."},{"issue":"9","key":"244_CR26","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archpsyc.61.9.905","volume":"61","author":"BA Johnson","year":"2004","unstructured":"Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry. 2004;61(9):905\u201312.","journal-title":"Arch Gen Psychiatry."},{"issue":"11","key":"244_CR27","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/j.1360-0443.2006.01576.x","volume":"101","author":"JZ Ma","year":"2006","unstructured":"Ma JZ, Ait-Daoud N, Johnson BA. Topiramate reduces the harm of excessive drinking: implications for public health and primary care. Addiction. 2006;101(11):1561\u20138.","journal-title":"Addiction."},{"issue":"14","key":"244_CR28","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","volume":"298","author":"BA Johnson","year":"2007","unstructured":"Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641\u201351.","journal-title":"JAMA."},{"issue":"11","key":"244_CR29","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1001\/archinte.168.11.1188","volume":"168","author":"BA Johnson","year":"2008","unstructured":"Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, et al. Improvement of physical health and quality of life of alcohol-dependent individuals with topiramate treatment: US multisite randomized controlled trial. Arch Intern Med. 2008;168(11):1188\u201399.","journal-title":"Arch Intern Med."},{"issue":"1","key":"244_CR30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/s-2004-815473","volume":"37","author":"G Rubio","year":"2004","unstructured":"Rubio G, Ponce G, Jimenez-Arriero MA, Palomo T, Manzanares J, Ferre F. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry. 2004;37(1):37\u201340.","journal-title":"Pharmacopsychiatry."},{"issue":"6","key":"244_CR31","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/JCP.0b013e3181bfdb79","volume":"29","author":"G Rubio","year":"2009","unstructured":"Rubio G, Martinez-Gras I, Manzanares J. Modulation of impulsivity by topiramate: implications for the treatment of alcohol dependence. J Clin Psychopharmacol. 2009;29(6):584\u20139.","journal-title":"J Clin Psychopharmacol."},{"issue":"5","key":"244_CR32","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.phrs.2005.05.012","volume":"52","author":"P Huguelet","year":"2005","unstructured":"Huguelet P, Morand-Collomb S. Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse. Pharmacol Res. 2005;52(5):392\u20134.","journal-title":"Pharmacol Res."},{"issue":"6","key":"244_CR33","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/j.1440-1819.2007.01718.x","volume":"61","author":"YH Chiu","year":"2007","unstructured":"Chiu YH, Lee TH, Shen WW. Use of low-dose topiramate in substance use disorder and bodyweight control. Psychiatry Clin Neurosci. 2007;61(6):630\u20133.","journal-title":"Psychiatry Clin Neurosci."},{"issue":"4","key":"244_CR34","first-page":"236","volume":"35","author":"JJ Fernandez Miranda","year":"2007","unstructured":"Fernandez Miranda JJ, Marina Gonzalez PA, Montes Perez M, Diaz Gonzalez T, Gutierrez Cienfuegos E, Antuna Diaz MJ, et al. Topiramate as add-on therapy in non-respondent alcohol dependant patients: a 12\u00a0month follow-up study. Actas Esp Psiquiatr. 2007;35(4):236\u201342.","journal-title":"Actas Esp Psiquiatr."},{"issue":"2","key":"244_CR35","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.drugalcdep.2013.06.032","volume":"133","author":"S Likhitsathian","year":"2013","unstructured":"Likhitsathian S, Uttawichai K, Booncharoen H, Wittayanookulluk A, Angkurawaranon C, Srisurapanont M. Topiramate treatment for alcoholic outpatients recently receiving residential treatment programs: a 12-week, randomized, placebo-controlled trial. Drug Alcohol Depend. 2013;133(2):440\u20136.","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"244_CR36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.drugalcdep.2013.05.026","volume":"133","author":"KM Kampman","year":"2013","unstructured":"Kampman KM, Pettinati HM, Lynch KG, Spratt K, Wierzbicki MR, O\u2019Brien CP. A double-blind, placebo-controlled trial of topiramate for the treatment of comorbid cocaine and alcohol dependence. Drug Alcohol Depend. 2013;133(1):94\u20139.","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"244_CR37","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jsat.2007.05.012","volume":"34","author":"AA Sousa De","year":"2008","unstructured":"De Sousa AA, De Sousa J, Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat. 2008;34(4):460\u20133.","journal-title":"J Subst Abuse Treat."},{"issue":"7","key":"244_CR38","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1111\/j.1530-0277.2008.00680.x","volume":"32","author":"G Florez","year":"2008","unstructured":"Florez G, Garcia-Portilla P, Alvarez S, Saiz PA, Nogueiras L, Bobes J. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol Clin Exp Res. 2008;32(7):1251\u20139.","journal-title":"Alcohol Clin Exp Res."},{"issue":"12","key":"244_CR39","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1111\/j.1360-0443.2008.02355.x","volume":"103","author":"DA Baltieri","year":"2008","unstructured":"Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction. 2008;103(12):2035\u201344.","journal-title":"Addiction."},{"issue":"1","key":"244_CR40","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000320471","volume":"17","author":"G Florez","year":"2011","unstructured":"Florez G, Saiz PA, Garcia-Portilla P, Alvarez S, Nogueiras L, Bobes J. Topiramate for the treatment of alcohol dependence: comparison with naltrexone. Eur Addict Res. 2011;17(1):29\u201336.","journal-title":"Eur Addict Res."},{"issue":"1","key":"244_CR41","first-page":"8","volume":"38","author":"B Arbaizar","year":"2010","unstructured":"Arbaizar B, Diersen-Sotos T, Gomez-Acebo I, Llorca J. Topiramate in the treatment of alcohol dependence: a meta-analysis. Actas Esp Psiquiatr. 2010;38(1):8\u201312.","journal-title":"Actas Esp Psiquiatr."},{"issue":"6","key":"244_CR42","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","volume":"38","author":"JC Blodgett","year":"2014","unstructured":"Blodgett JC, Del Re AC, Maisel NC, Finney JW. A meta-analysis of topiramate\u2019s effects for individuals with alcohol use disorders. Alcohol Clin Exp Res. 2014;38(6):1481\u20138.","journal-title":"Alcohol Clin Exp Res."},{"issue":"2","key":"244_CR43","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","volume":"108","author":"NC Maisel","year":"2013","unstructured":"Maisel NC, Blodgett JC, Wilbourne PL, Humphreys K, Finney JW. Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful? Addiction. 2013;108(2):275\u201393.","journal-title":"Addiction."},{"key":"244_CR44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1471-244X-11-41","volume":"11","author":"T Paparrigopoulos","year":"2011","unstructured":"Paparrigopoulos T, Tzavellas E, Karaiskos D, Kourlaba G, Liappas I. Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study. BMC Psychiatry. 2011;11:41.","journal-title":"BMC Psychiatry."},{"issue":"6","key":"244_CR45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/JCP.0000000000000228","volume":"34","author":"G Martinotti","year":"2014","unstructured":"Martinotti G, Di Nicola M, De Vita O, Hatzigiakoumis DS, Guglielmo R, Santucci B, et al. Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study. J Clin Psychopharmacol. 2014;34(6):709\u201315.","journal-title":"J Clin Psychopharmacol."},{"issue":"3","key":"244_CR46","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1530-0277.2007.00592.x","volume":"32","author":"R Miranda Jr","year":"2008","unstructured":"Miranda R Jr, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res. 2008;32(3):489\u201397.","journal-title":"Alcohol Clin Exp Res."},{"issue":"4","key":"244_CR47","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1176\/appi.ajp.2013.13081014","volume":"171","author":"HR Kranzler","year":"2014","unstructured":"Kranzler HR, Covault J, Feinn R, Armeli S, Tennen H, Arias AJ, et al. Topiramate treatment for heavy drinkers: moderation by a GRIK1 polymorphism. Am J Psychiatry. 2014;171(4):445\u201352.","journal-title":"Am J Psychiatry."},{"issue":"2","key":"244_CR48","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1037\/a0015700","volume":"17","author":"LA Ray","year":"2009","unstructured":"Ray LA, Miranda R Jr, MacKillop J, McGeary J, Tidey JW, Rohsenow DJ, et al. A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol. 2009;17(2):122\u20139.","journal-title":"Exp Clin Psychopharmacol."},{"issue":"4","key":"244_CR49","first-page":"211","volume":"56","author":"A Rustembegovic","year":"2002","unstructured":"Rustembegovic A, Sofic E, Kroyer G. A pilot study of Topiramate (Topamax) in the treatment of tonic\u2013clonic seizures of alcohol withdrawal syndromes. Med Arh. 2002;56(4):211\u20132.","journal-title":"Med Arh."},{"issue":"4","key":"244_CR50","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1530-0277.2007.00344.x","volume":"31","author":"EM Krupitsky","year":"2007","unstructured":"Krupitsky EM, Rudenko AA, Burakov AM, Slavina TY, Grinenko AA, Pittman B, et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res. 2007;31(4):604\u201311.","journal-title":"Alcohol Clin Exp Res."},{"issue":"1","key":"244_CR51","first-page":"13","volume":"22","author":"J Littleton","year":"1998","unstructured":"Littleton J. Neurochemical mechanisms underlying alcohol withdrawal. Alcohol Health Res World. 1998;22(1):13\u201324.","journal-title":"Alcohol Health Res World."},{"issue":"Suppl 2","key":"244_CR52","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1590\/S1516-44462009000600004","volume":"31","author":"PA Prado-Lima","year":"2009","unstructured":"Prado-Lima PA. Pharmacological treatment of impulsivity and aggressive behaviour [in Portuguese]. Rev Bras Psiquiatr. 2009;31(Suppl 2):S58\u201365.","journal-title":"Rev Bras Psiquiatr."},{"issue":"1","key":"244_CR53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/YCO.0b013e32831575d9","volume":"22","author":"KS Leung","year":"2009","unstructured":"Leung KS, Cottler LB. Treatment of pathological gambling. Curr Opin Psychiatry. 2009;22(1):69\u201374.","journal-title":"Curr Opin Psychiatry."},{"issue":"2","key":"244_CR54","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2165\/00023210-200923020-00004","volume":"23","author":"SL McElroy","year":"2009","unstructured":"McElroy SL, Guerdjikova AI, Martens B, Keck PE Jr, Pope HG, Hudson JI. Role of antiepileptic drugs in the management of eating disorders. CNS Drugs. 2009;23(2):139\u201356.","journal-title":"CNS Drugs."},{"issue":"5","key":"244_CR55","doi-asserted-by":"crossref","first-page":"716","DOI":"10.4088\/JCP.09m05266gre","volume":"72","author":"HA Berlin","year":"2011","unstructured":"Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive\u2013compulsive disorder. J Clin Psychiatry. 2011;72(5):716\u201321.","journal-title":"J Clin Psychiatry."},{"issue":"12","key":"244_CR56","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/archpsyc.1993.01820240059008","volume":"50","author":"CR Cloninger","year":"1993","unstructured":"Cloninger CR, Svrakic DM, Przybeck TR. A psychobiological model of temperament and character. Arch Gen Psychiatry. 1993;50(12):975\u201390.","journal-title":"Arch Gen Psychiatry."},{"issue":"4","key":"244_CR57","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","volume":"9","author":"B Bandelow","year":"2008","unstructured":"Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ, Allgulander C, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive\u2013compulsive and post-traumatic stress disorders\u2014first revision. World J Biol Psychiatry. 2008;9(4):248\u2013312.","journal-title":"World J Biol Psychiatry."},{"key":"244_CR58","volume-title":"Diagnostic and statistical manual of mental disorders, DSM-IV","author":"American Psychiatric Association","year":"1994","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, DSM-IV. 4th ed. Washington, DC: American Psychiatric Association; 1994.","edition":"4"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0244-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-015-0244-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-015-0244-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T13:10:42Z","timestamp":1691586642000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-015-0244-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,22]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["244"],"URL":"https:\/\/doi.org\/10.1007\/s40263-015-0244-0","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,22]]}}}